A unique range of integrated early stage development services to support biopharmaceutical drug development.

Solutions through experience

This extensive suite of services combines Cellca’s cell line and upstream process development expertise with BioOutsource’s bioanalytical and biosafety contract testing expertise to support customers from cell line development, through product manufacture and release. Broadening Sartorius Stedim Biotech’s portfolio of products, technologies and services and enabling a comprehensive “Total Solution” to support our clients’ drug development activities.

Benefit from the combined experience of Cellca, BioOutsource and Sartorius Stedim Biotech to efficiently advance your drug candidates quickly from early stage development through to commercialisation.

Accelerated drug development

Based on its unparalleled global experience working to support biological drug development, BioOutsource and Cellca lead the way in preclinical development. Through our robust platforms, off-the-shelf assays and commitment to providing a total solution, Sartorius Stedim Biotech can accelerate your drug’s development.

Biosimilar expertise

BioOutsource and Cellca have industry leading expertise in supporting biosimilar drug development. Collectively we have worked with over 50 biosimilar developers across 12 countries, totalling 230 biosimilar projects. Benefit from our combined experience and integrated services to further mitigate risks and select optimal biosimilar clones. Find out more.

Customers first

Our service offering is underpinned by our commitment to delivering excellent customer service, navigating our customers through the complexities of the drug development cycle and enabling them to make informed data-driven decisions. Our client management team provide an intimate customer experience and ensure your project is managed efficiently and delivered on time. Effective communication is key to success, and our team understand that a transparent, proactive approach to customer service will ensure the delivery of a truly differentiated solution.

Contact our experts today to discuss your drug development programmes.


Sartorius Stedim Biotech Opens New Bioanalytical Testing Laboratory

New services to enable U.S. biopharmaceutical companies to accelerate development of biosimilar. Goettingen, Germany | Boston, MA, USA – November 10, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new bioanalytical and biosafety testing laboratory yesterday in the major biotech hub of Boston, Massachusetts. This dedicated bioanalytical laboratory More

Sartorius Stedim BioOutsource Introduces New Released N-Glycan Assay

In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data   Glasgow, UK – July 7, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launched of a new Released N-Glycan Assay for the in-depth profiling of IgG glycosylation. This new physico-chemical assay, More

Sartorius Stedim BioOutsource Appoints Technical Sales Specialist in India

To help Indian researchers access a portfolio of excellent services from BioOutsource and Cellca Glasgow, UK – June 29, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, is pleased to announce that its subsidiary BioOutsource has appointed Ravin Mehta as Technical Sales Specialist to enable customers to have access to More